Evidence map›Paper›PMID 34155970›Full record

ArticleeLife2021

Smartphone screen testing, a novel pre-diagnostic method to identify SARS-CoV-2 infectious individuals.

Rodrigo M Young, Camila J Solis, Andres Barriga-Fehrman, Carlos Abogabir, Alvaro R Thadani, Mariana Labarca, Eva Bustamante, Cecilia V Tapia, Antonia G Sarda, Francisca Sepulveda and 9 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Rodrigo M YoungDiagnosis Biotech, Santiago, Chile.ORCID 0000-0001-5765-197X
Camila J SolisDiagnosis Biotech, Santiago, Chile.ORCID 0000-0002-7195-523X
Andres Barriga-FehrmanDiagnosis Biotech, Santiago, Chile.
Carlos AbogabirDiagnosis Biotech, Santiago, Chile.
Alvaro R ThadaniDiagnosis Biotech, Santiago, Chile.ORCID 0000-0002-2541-1709
Mariana LabarcaDiagnosis Biotech, Santiago, Chile.ORCID 0000-0001-6455-3569
Eva BustamanteGrupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile.ORCID 0000-0002-3125-8608
Cecilia V TapiaLaboratorio de Especialidad, Clínica Dávila, Santiago, Chile.ORCID 0000-0001-6234-2100
Antonia G SardaLaboratorio de Especialidad, Clínica Dávila, Santiago, Chile.
Francisca SepulvedaLaboratorio de Especialidad, Clínica Dávila, Santiago, Chile.ORCID 0000-0002-8144-0096
Nadia PozasLaboratorio de Especialidad, Clínica Dávila, Santiago, Chile.
Leslie C CerpaLaboratory of Chemical Carcinogenesis and Pharmacogenetics (Chilean Health Council Diagnostic Covid19 Laboratory), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID 0000-0002-9525-389X
María A LavanderosLaboratory of Chemical Carcinogenesis and Pharmacogenetics (Chilean Health Council Diagnostic Covid19 Laboratory), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID 0000-0001-6167-0508
Nelson M VarelaLaboratory of Chemical Carcinogenesis and Pharmacogenetics (Chilean Health Council Diagnostic Covid19 Laboratory), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID 0000-0002-5229-3007
Alvaro SantibañezCentro de Biotecnología Acuícola, Facultad de Química y Biología, Santiago, Chile.ORCID 0000-0001-9330-2961
Ana M SandinoCentro de Biotecnología Acuícola, Facultad de Química y Biología, Santiago, Chile.ORCID 0000-0002-3862-3743
Felipe Reyes-LopezCentro de Biotecnología Acuícola, Facultad de Química y Biología, Santiago, Chile.ORCID 0000-0002-5001-457X
Garth DixonDepartment of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID 0000-0001-8165-3094
Luis A QuiñonesLaboratory of Chemical Carcinogenesis and Pharmacogenetics (Chilean Health Council Diagnostic Covid19 Laboratory), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID 0000-0002-7967-5320
Clínica Dávila · CLUniversity of Chile · CLUniversidad de Santiago de Chile · CLAgriaquaculture Nutritional Genomic Center · CLUniversitat Autònoma de Barcelona · ESUniversity College London · GB

Funding

Agencia Nacional de Investigación e Innovación ANID-Covid0789Agencia Nacional de Investigación e Innovación ANID-Covid1038Agencia Nacional de Investigacion y Desarrollo Chile ANID-Covid0789Agencia Nacional de Investigacion y Desarrollo Chile ANID-Covid1038Fondecyt 1211841FONDECYT 1211841Moorfields Eye Charity Career Development Award 001155Moorfields Eye Charity Springboard Award GR001210Moorfields Eye Hospital NHS Foundation Trust 001155Moorfields Eye Hospital NHS Foundation Trust GR001210
6 · The paper itself

Abstract

The COVID-19 pandemic will likely take years to control globally, and constant epidemic surveillance will be required to limit the spread of SARS-CoV-2, especially considering the emergence of new variants that could hamper the effect of vaccination efforts. We developed a simple and robust -

Indexed as

COVID-19COVID-19 Nucleic Acid TestingPandemicsSmartphoneHumansSARS-CoV-2COVID-19infectious diseasemicrobiologyRT-PCRSARS-CoV-2virus

Identifiers

PMID34155970
PMCPMC8275127
OpenAlexW3177072957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.